

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation 2 issues pertaining to equality were highlighted;

1. Age; Myelofibrosis is more prevalent in older people and this could be a disadvantage in the economic analysis
2. Myelofibrosis is a rare form of cancer

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

1. NICE is committed to avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity. However, issues related to differences in prevalence or incidence of a disease between different age groups cannot be addressed in a technology appraisal.
2. The rare nature of a condition is not an equality issue.

3. Has any change to the draft scope been agreed to highlight potential

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289)

Issue date: April 2015

equality issues?
Not required

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
Not required

**Approved by Associate Director (name): Frances Sutcliffe**

**Date: 13 04 2015**